NYSE · Drug Manufacturers - General · USD
AbbVie Inc. (ABBV) Stock Analysis
AbbVie Inc. (ABBV) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ABBV Key Statistics
As of Oct 21, 2026Trading
- Open
- $287.63
- Previous Close
- $289.08
- Day's Range
- 282.16–289.00
- 52-Week Range
- 190.75–291.40
- Volume
- 4.39M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.23
Valuation
- Market Cap
- $503.27B
- P/E Ratio
- 80.45
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 17.58
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 0.59
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 7.82
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 3.54
Financials (FY)
- Revenue (FY)
- $61.16B+8.57%
- Net Income (FY)
- $4.23B−1.22%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 9.80%
- Shares Outstanding
- 1.77B
- 1-Year Return
- +26.77%
Dividend and dates
- Dividend
- $6.92+2.39%
- Ex-Dividend Date
- October 15, 2026
- Earnings Date
- October 30, 2026
- Avg Volume
- 4.85M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ABBV closed at $284.80, +26.77% over 1 year.
AbbVie Inc. (ABBV) has a market capitalization of $503.27B.
In fiscal 2025, ABBV reported revenue of $61.16B.
ABBV Stock Return by Calendar Year
AbbVie Inc. (ABBV) 10-year return: what $10,000 became
- 1 year
- $10,000 $12,677
- +26.77%
- 5 years
- $10,000 $31,275
- +212.75%
- 10 years
- $10,000 $70,190
- +601.90%
If you had invested $10,000 in AbbVie Inc. (ABBV) 10 years ago, at the close on October 21, 2016, it would have been worth $70,190 at the close on October 21, 2026: +601.90% in total, +21.51% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +28.37% |
| 2025 | +33.08% |
| 2024 | +18.86% |
| 2023 | −0.23% |
| 2022 | +24.01% |
| 2021 | +32.43% |
| 2020 | +27.72% |
| 2019 | +1.47% |
| 2018 | −0.96% |
| 2017 | +60.07% |
| 2016 (partial year) | −5.32% |
As of October 21, 2026.
ABBV Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $61.16B | $4.23B | 6.9% |
| 2024 | $56.33B | $4.28B | 7.6% |
| 2023 | $54.32B | $4.86B | 9.0% |
| 2022 | $58.05B | $11.84B | 20.4% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $61.16B | $42.96B | $20.09B | $4.23B | 6.9% |
| 2024 | $56.33B | $39.43B | $11.89B | $4.28B | 7.6% |
| 2023 | $54.32B | $33.90B | $13.54B | $4.86B | 9.0% |
| 2022 | $58.05B | $40.64B | $18.81B | $11.84B | 20.4% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ABBV Dividend History
Dividends per share, 2025 · 4 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $6.92 | 4 | — |
| 2025 | $6.56 | 4 | +5.8% |
| 2024 | $6.20 | 4 | +4.7% |
| 2023 | $5.92 | 4 | +5.0% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $6.92 | 4 | — |
| 2025 | $6.56 | 4 | +5.8% |
| 2024 | $6.20 | 4 | +4.7% |
| 2023 | $5.92 | 4 | +5.0% |
| 2022 | $5.64 | 4 | +8.5% |
| 2021 | $5.20 | 4 | +10.2% |
| 2020 | $4.72 | 4 | +10.3% |
| 2019 | $4.28 | 4 | +19.2% |
| 2018 | $3.59 | 4 | +40.2% |
| 2017 | $2.56 | 4 | — |
Most recent payment: $1.73 per share, ex-dividend October 15, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
ABBV Valuation vs Drug Manufacturers - General Median
Median of 21 stocks| Metric | ABBV | Drug Manufacturers - General median | vs median |
|---|---|---|---|
| P/E | 80.45 | 25.23 | 3.2x the median |
| P/S ratio | 7.82 | 3.23 | 142% above |
| Profit margin | 9.80% | 9.80% | 0.0 pts above |
Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
AbbVie races into F1 as pharma companies continue push into sport
pharmaceutical-technology.comAbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer
YahooAbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
The Motley FoolSpyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
YahooCan This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
YahooAbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
Yahoo
All 20 articles ↓Show fewer ↑
AbbVie Inks Multi-Year Collaboration With McLaren Racing To Be Its Official Pharmaceutical Partner Of McLaren Mastercard Formula 1 Team
BenzingaAbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial. Here’s What It Means for a Stock Up 24% in 2026
TIKRAbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts
YahooAbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?
YahooAbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
YahooZacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie
YahooAbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
YahooAbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease
BenzingaReported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW
BenzingaReported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients
Benzinga/C O R R E C T I O N - AbbVie/
YahooAbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
YahooAbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
24/7 Wall St.Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
The Motley Fool
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - General Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
MRKMerck & Co., Inc.
$369.78B
NVSNovartis AG
$292.58B
AZNAstraZeneca PLC
$261.82B
AMGNAmgen Inc.
$236.98B
Popular Healthcare Stocks
UnitedHealth Group Incorporated
$374.30B
TMOThermo Fisher Scientific Inc.
$256.61B
GILDGilead Sciences, Inc.
$190.42B
ABTAbbott Laboratories
$173.92B
NVONovo Nordisk A/S
$172.38B